The bepirovirsen phase 3 trial, reported in The New England Journal of Medicine, introduces a mechanistically distinct approach to hepatitis B treatment with important clinical implications. Rather than relying on viral suppression alone, this antisense oligonucleotide therapy targets hepatitis B virus RNA to reduce surface antigen production—addressing a fundamental limitation of nucleoside analogues that achieve viral suppression without hepatitis B surface antigen loss.
For clinicians managing the 296 million patients with chronic hepatitis B globally, bepirovirsen represents a potential paradigm shift toward functional cure as a realistic treatment goal. The trial’s primary endpoints—sustained hepatitis B surface antigen loss and undetectable HBV DNA—reflect World Health Organization standards for functional cure, offering objective measures of therapeutic success. Understanding this novel mechanism and its potential advantages over conventional therapies is essential for medical professionals evaluating treatment options and discussing realistic outcomes with patients.
Read the full article on GMJ Newsroom.
Was this article helpful?
